Premium
P4‐397: Memantine treatment prevents clinical worsening: A pooled analysis of patients with moderate to severe Alzheimer's disease
Author(s) -
Tocco Michael,
Graham Stephen M.
Publication year - 2008
Publication title -
alzheimer's and dementia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.713
H-Index - 118
eISSN - 1552-5279
pISSN - 1552-5260
DOI - 10.1016/j.jalz.2008.05.2467
Subject(s) - memantine , donepezil , placebo , medicine , clinical trial , context (archaeology) , concomitant , disease , dementia , pathology , paleontology , alternative medicine , biology
age 49, with or without cognitive concerns, access the Registry via outreach events, telephone, or the Internet (www.registry.azalz.org). An initial intake form is completed and questions are addressed by telephone. Interested PP’s receive a welcome packet, consent form, and medical history form; these are reviewed by telephone upon their return. Cognitive screening occurs via a cognitive and functional questionnaire and the modified Telephone Interview based Cognitive Screen (TICSm); those with ambiguous scores undergo a version of the Auditory Verbal Learning Task (Rey AVLT). Based on review of medical information and testing, PP’s are categorized as probably cognitively normal, possibly cognitively impaired, or probably demented, and referred to existing AAC studies or held for future referral. Results: The database stores PP contact information, research interest, cognitive status, demographics and referral information. After consent, it is used to track and facilitate PP enrollment and contacts, store comprehensive medical information, facilitate cognitive testing, and initiate and track study referrals with the AAC. It also catalogues clinical study and site information for all AAC sites. Conclusions: A companion presentation (Arizona Alzheimer’s Registry II: Progress and Data from Year 1; Holt et al) summarizes the unexpected early success of this initiative, which may offer a model for other organizations.